81.81

3.31% -2.80

Edwards Lifesciences Corp (EW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$84.61

Offen:

$85.13

24-Stunden-Volumen:

5.62M

Relative Volume:

1.35

Marktkapitalisierung:

$47.52B

Einnahmen:

$6.07B

Nettoeinkommen (Verlust:

$1.06B

KGV:

45.29

EPS:

1.8063

Netto-Cashflow:

$1.34B

1W Leistung:

+0.21%

1M Leistung:

+7.83%

6M Leistung:

+5.47%

1J Leistung:

+20.40%

1-Tages-Spanne:

$81.34

$85.33

1-Wochen-Bereich:

$80.54

$86.38

52-Wochen-Spanne:

$65.94

$87.89

Edwards Lifesciences Corp Stock (EW) Company Profile

Firmenname

Edwards Lifesciences Corp

Sektor

Healthcare (1116)

Branche

Medical Devices (144)

Telefon

(949) 250-2500

Adresse

ONE EDWARDS WAY, IRVINE, CA

Mitarbeiter

16,000

Twitter

@edwardslifesci

Nächster Verdiensttermin

2026-04-22

Neueste SEC-Einreichungen

EW's Discussions on Twitter

Compare EW vs ABT, SYK, MDT, BSX

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EW Edwards Lifesciences Corp	81.81	47.52B	6.07B	1.06B	1.34B	1.8063
ABT Abbott Laboratories	108.03	187.72B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	336.77	128.88B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.14	111.88B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	69.13	102.58B	20.08B	2.89B	3.66B	1.9391

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-09	Hochstufung	TD Cowen	Hold → Buy
2025-12-18	Hochstufung	JP Morgan	Neutral → Overweight
2025-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2025-10-29	Hochstufung	Jefferies	Hold → Buy
2025-10-29	Hochstufung	Wolfe Research	Underperform → Peer Perform
2025-10-08	Herabstufung	Oppenheimer	Outperform → Perform
2025-10-07	Hochstufung	Evercore ISI	In-line → Outperform
2025-07-29	Hochstufung	BTIG Research	Neutral → Buy
2025-04-24	Hochstufung	Piper Sandler	Neutral → Overweight
2025-01-30	Hochstufung	Stifel	Hold → Buy
2025-01-16	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-12-16	Hochstufung	BofA Securities	Neutral → Buy
2024-10-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-09-18	Herabstufung	Jefferies	Buy → Hold
2024-07-31	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-07-29	Hochstufung	Wolfe Research	Underperform → Peer Perform
2024-07-25	Herabstufung	BofA Securities	Buy → Neutral
2024-07-25	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-25	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-07-25	Herabstufung	TD Cowen	Buy → Hold
2024-07-25	Herabstufung	Truist	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2024-05-22	Hochstufung	Citigroup	Neutral → Buy
2024-05-14	Hochstufung	Deutsche Bank	Hold → Buy
2024-03-07	Hochstufung	BofA Securities	Neutral → Buy
2024-02-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-01-04	Herabstufung	Evercore ISI	Outperform → In-line
2023-12-11	Herabstufung	Citigroup	Buy → Neutral
2023-11-28	Herabstufung	Wolfe Research	Peer Perform → Underperform
2023-09-26	Hochstufung	Oppenheimer	Perform → Outperform
2023-07-19	Eingeleitet	Robert W. Baird	Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Overweight
2023-03-29	Eingeleitet	UBS	Neutral
2023-03-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-02-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-31	Herabstufung	Bernstein	Outperform → Underperform
2023-01-30	Herabstufung	Piper Sandler	Overweight → Neutral
2022-12-06	Herabstufung	Stifel	Buy → Hold
2022-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2022-10-26	Eingeleitet	Mizuho	Buy
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Buy
2022-07-29	Herabstufung	Canaccord Genuity	Buy → Hold
2022-04-13	Eingeleitet	Truist	Buy
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-03-16	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-27	Bestätigt	Citigroup	Buy
2022-01-27	Bestätigt	Evercore ISI	Outperform
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	Stifel	Buy
2022-01-27	Bestätigt	UBS	Neutral
2021-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-12-15	Hochstufung	Citigroup	Neutral → Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-12-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-07-30	Bestätigt	Canaccord Genuity	Buy
2021-07-30	Bestätigt	Deutsche Bank	Hold
2021-07-30	Bestätigt	Jefferies	Buy
2021-07-30	Bestätigt	Morgan Stanley	Overweight
2021-07-30	Bestätigt	Oppenheimer	Outperform
2021-07-30	Bestätigt	Stifel	Buy
2021-07-30	Bestätigt	UBS	Neutral
2021-07-30	Bestätigt	Wells Fargo	Equal Weight
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-04-05	Hochstufung	Evercore ISI	In-line → Outperform
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-12-11	Bestätigt	Canaccord Genuity	Buy
2020-09-11	Eingeleitet	Wolfe Research	Underperform
2020-04-28	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-10	Eingeleitet	Oppenheimer	Outperform
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-10-24	Bestätigt	Canaccord Genuity	Buy
2019-09-23	Eingeleitet	Piper Jaffray	Overweight
2019-07-24	Bestätigt	BofA/Merrill	Buy
2019-03-18	Bestätigt	Canaccord Genuity	Buy
2019-01-18	Hochstufung	BofA/Merrill	Neutral → Buy
2019-01-03	Eingeleitet	Deutsche Bank	Hold
2018-11-28	Eingeleitet	UBS	Neutral
2018-10-16	Eingeleitet	Barclays	Underweight
2018-10-02	Herabstufung	BofA/Merrill	Buy → Neutral
2018-10-02	Herabstufung	Guggenheim	Buy → Neutral

Alle ansehen

Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten

08:09 AM

Wellington Management Group LLP Buys 977,933 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

08:09 AM

04:39 AM

Chesapeake Capital Corp IL Makes New $1 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat

04:39 AM

Mar 13, 2026

Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch

Mar 13, 2026

Edwards Lifesciences Hits Day High with Strong 3.21% Intraday Surge - Markets Mojo

Mar 13, 2026

Edwards Lifesciences (EW) slips 3.3% as investors digest recent conference remarks and insider-selling filings - Quiver Quantitative

Mar 13, 2026

Edwards Lifesciences Corp. Experiences Evaluation Revision Amidst Strong Market Performance - Markets Mojo

Mar 13, 2026

Van ECK Associates Corp Reduces Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 13, 2026

Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It? - Yahoo Finance

Mar 13, 2026

Connor Clark & Lunn Investment Management Ltd. Has $42.22 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 13, 2026

Edwards Lifesciences Corporation $EW Shares Bought by Bank of Montreal Can - MarketBeat

Mar 13, 2026

Mar 12, 2026

How The Edwards Lifesciences (EW) Story Is Shifting As 2026 Expectations Tighten - Yahoo Finance

Mar 12, 2026

WINTON GROUP Ltd Sells 57,665 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

Mar 12, 2026

Natixis Advisors LLC Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 12, 2026

Grantham Mayo Van Otterloo & Co. LLC Acquires New Position in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 12, 2026

A Look At Edwards Lifesciences (EW) Valuation As It Exits Critical Care To Focus On Core Heart Therapies - simplywall.st

Mar 12, 2026

Mar 11, 2026

Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus

Mar 11, 2026

Edwards Lifesciences (NYSE: EW) brokered cashless option exercise on 03/11/2026 - Stock Titan

Mar 11, 2026

Edwards Lifesciences at Leerink Conference: Strategic Growth and Innovation - Investing.com

Mar 11, 2026

Edwards Lifesciences Corporation $EW Shares Sold by Swiss National Bank - MarketBeat

Mar 11, 2026

Mar 10, 2026

Edwards Lifesciences at Barclays: Strategic Growth Focus - Investing.com

Mar 10, 2026

Edwards Lifesciences at Barclays Conference: Strategic Growth Focus By Investing.com - Investing.com Canada

Mar 10, 2026

Edwards Lifesciences at Barclays Conference: Strategic Growth Focus - Investing.com

Mar 10, 2026

Korea Investment CORP Purchases 46,317 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

Mar 10, 2026

Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 10, 2026

Mar 09, 2026

Edwards Lifesciences jumps 3.21% with $400M traded, placing 368th in volume; revenue growth exceeds earnings shortfall - Bitget

Mar 09, 2026

Is Edwards Lifesciences Stock Outperforming the S&P 500? - Yahoo Finance

Mar 09, 2026

Niranjan Pai joins Edwards Lifesciences as Director-Government Affairs - Exchange4Media

Mar 09, 2026

Inceptionr LLC Makes New $1.61 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 09, 2026

Edwards Lifesciences Corporation $EW Shares Acquired by Russell Investments Group Ltd. - MarketBeat

Mar 09, 2026

Rathbones Group PLC Has $6.84 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 09, 2026

Mar 08, 2026

Is Edwards Lifesciences (EW) Pricing Look Stretched After Recent Share Price Swings - Yahoo Finance

Mar 08, 2026

Rhenman & Partners Asset Management AB Has $12.05 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 08, 2026

Blair William & Co. IL Has $28.96 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Mar 08, 2026

Mar 06, 2026

How Edwards Lifesciences Corporation stock performs during Fed tightening cyclesJuly 2025 Weekly Recap & Consistent Profit Alerts - Naître et grandir

Mar 06, 2026